Sodium phenylbutyrate/ursodoxicoltaurine

From WikiProjectMed
(Redirected from AMX0035)
Jump to navigation Jump to search
Sodium phenylbutyrate/ursodoxicoltaurine
Combination of
Sodium phenylbutyratePan-histone deacetylase inhibitor
UrsodoxicoltaurineBile acid
Names
Trade namesAlbrioza, Relyvrio
Other namesSodium phenylbutyrate / taurursodiol; sodium phenylbutyrate / tauroursodeoxycholic acid; AMX0035
Clinical data
Main usesNone[1]
Side effectsDiarrhea, abdominal pain, nausea, upper respiratory tract infection[2]
Routes of
use		By mouth
Legal
Legal status

Sodium phenylbutyrate/ursodoxicoltaurine, also known as sodium phenylbutyrate/taurursodiol and sold under the brand name Albrioza among others, was a combination medication used to treat amyotrophic lateral sclerosis (ALS).[4][2] It was subsequently shown to not be effective in 2024.[1] It is given by mouth.[2]

Common side effects include diarrhea, abdominal pain, nausea, and upper respiratory tract infection.[2] It is high in sodium and care should be taken in those who are sensitive.[2] Use in pregnancy may harm the baby.[2] It contains sodium phenylbutyrate and ursodoxicoltaurine (taurursodiol).[4] It was believed to work by altering pathways in mitochondria and endoplasmic reticulum that result in cell death.[6]

The combination was approved for medical use in Canada and the United States in 2022.[4][2] The manufacturer has applied for approve in Europe as of 2022.[6] In Canada it costs about 220,000 CAD per person per year.[7] In the United States it costs about 158,000 USD per year as of 2022.[8] It was withdrawn from the market in 2024.[1]

Medical uses

Sodium phenylbutyrate/ursodoxicoltaurine is indicated for the treatment of amyotrophic lateral sclerosis (ALS).[4][2][5]

Dosage

It is used at a dose of 3 g sodium phenylbutyrate and 1 g taurursodiol once a day for 3 weeks, and than this dose is taken twice per day.[2]

Mechanism of action

It acts by blocking cell death pathways in mitochondria and in the endoplasmic reticulum.[9] Sodium phenylbutyrate is a chemical chaperone that helps proteins maintain their normal conformation, preventing aggregation that may lead to cell death.[9] Ursodoxicoltaurine improves mitochondrial energy production.[9]

History

In a phase II/III clinical trial, CENTAUR, for ALS sodium phenylbutyrate/ursodoxicoltaurine (AMX0035) showed increased survival times.[10][11][12][13][14]

A phase II trial for Alzheimer's disease, PEGASUS, confirmed the safety and tolerability of sodium phenylbutyrate/ursodoxicoltaurine.[15]

The efficacy of sodium phenylbutyrate/ursodoxicoltaurine for the treatment of ALS was demonstrated in a 24-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study.[16][17] In the trial, 137 adult participants with ALS were randomized to receive either sodium phenylbutyrate/ursodoxicoltaurine or placebo.[16] The participants treated with sodium phenylbutyrate/ursodoxicoltaurine experienced a slower rate of decline on a clinical assessment of daily functioning compared to those receiving a placebo.[16] Additionally, longer overall survival was observed in a post hoc, long-term analysis of participants who originally received sodium phenylbutyrate/ursodoxicoltaurine versus those who originally received placebo.[16]

The US Food and Drug Administration (FDA) granted the application for the combination priority review and orphan drug designations.[16] The FDA granted the approval of Relyvrio to Amylyx Pharmaceuticals Inc.[16]

Society and culture

Controversies

The FDA approval is controversial because of the small size of the trial. The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted not to recommend approval, and then in an unusual second vote recommended approval.[18][19]

Research

It is being studied as a treatment for Alzheimer's disease[20][21] and Wolfram syndrome.[22]

References

  1. ↑ 1.0 1.1 1.2 "ALS drug pulled from market in Canada, U.S. after failing late-stage clinical trial". CBC. Archived from the original on 5 April 2024. Retrieved 4 April 2024.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 "Relyvrio- sodium phenylbutyrate/taurursodiol powder, for suspension". DailyMed. 30 September 2022. Archived from the original on 16 October 2022. Retrieved 16 October 2022.
  3. ↑ "Qualifying notice for Albrioza". Health Canada. 13 June 2022. Archived from the original on 14 June 2022. Retrieved 13 June 2022.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 "Albrioza monograph" (PDF). 1 June 2022. Archived (PDF) from the original on 14 June 2022. Retrieved 14 June 2022.
  5. ↑ 5.0 5.1 "Drug Approval Package: Relyvrio". U.S. Food and Drug Administration (FDA). 27 October 2022. Archived from the original on 18 November 2022. Retrieved 18 November 2022.
  6. ↑ 6.0 6.1 "Sodium phenylbutyrate + tauroursodeoxycholic acid". SPS - Specialist Pharmacy Service. 20 November 2020. Archived from the original on 26 November 2021. Retrieved 16 December 2022.
  7. ↑ "Sodium Phenylbutyrate and Ursodoxicoltaurine (Albrioza)". Canadian Journal of Health Technologies. 8 August 2022. doi:10.51731/cjht.2022.410. Archived from the original on 16 December 2022. Retrieved 16 December 2022.
  8. ↑ "Amylyx sets ALS drug price at $158,000 per year, opening new debate on cost". BioPharma Dive. Archived from the original on 16 December 2022. Retrieved 16 December 2022.
  9. ↑ 9.0 9.1 9.2 "AMX0035". alsnewstoday. Archived from the original on 28 May 2021. Retrieved 15 June 2021.
  10. ↑ Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. (September 2020). "Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis". The New England Journal of Medicine. 383 (10): 919–930. doi:10.1056/NEJMoa1916945. PMC 9134321. PMID 32877582.
  11. ↑ Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. (January 2021). "Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis". Muscle & Nerve. 63 (1): 31–39. doi:10.1002/mus.27091. PMC 7820979. PMID 33063909.
  12. ↑ "Novel ALS Drug Continues to Show Survival Benefit". medpagetoday.com. 19 April 2021. Archived from the original on 19 May 2021. Retrieved 15 June 2021.
  13. ↑ Paganoni S, Hendrix S, Dickson S, Knowlton N, Macklin E, Cohen J, et al. (13 April 2021). "Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS (4550)". Neurology. 96 (15 Supplement). Archived from the original on 13 August 2021. Retrieved 15 June 2021.
  14. ↑ "Long-term survival outcomes of AMX0035 for ALS". 22 April 2021. Archived from the original on 14 June 2022. Retrieved 15 June 2021.
  15. ↑ "AMX0035 Meets Primary Safety and Tolerability End Point in Alzheimer Disease". Neurology live. Archived from the original on 21 November 2021. Retrieved 9 April 2022.
  16. ↑ 16.0 16.1 16.2 16.3 16.4 16.5 "FDA Approves New Treatment Option for Patients with ALS". U.S. Food and Drug Administration (FDA) (Press release). 29 September 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  17. ↑ "AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) (CENTAUR)". ClinicalTrials.gov. 25 April 2017. Archived from the original on 23 September 2022. Retrieved 29 September 2022.
  18. ↑ "ALS drug's approval draws cheers from patients, questions from skeptics". NPR. 30 September 2022. Archived from the original on 1 October 2022. Retrieved 30 September 2022.
  19. ↑ Howard, Jacqueline (29 September 2022). "ALS drug gets FDA approval despite uncertainty about effectiveness". CNN. Archived from the original on 29 September 2022. Retrieved 30 September 2022.
  20. ↑ "AMX0035 to Treat Alzheimer's Disease". alzheimers.gov. Archived from the original on 14 June 2022. Retrieved 15 June 2021.
  21. ↑ "AMX0035". alzforum.org. Archived from the original on 13 June 2021. Retrieved 15 June 2021.
  22. ↑ "Amylyx Pipeline". amylyx.com. Archived from the original on 24 June 2021. Retrieved 15 June 2021. We are currently exploring the potential of AMX0035 as a treatment option for ALS, Alzheimer’s disease and Wolfram syndrome

External links

Identifiers:
  • "Sodium phenylbutyrate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-09-29. Retrieved 2022-11-18.
  • "Taurursodiol". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-09-29. Retrieved 2022-11-18.
Retrieved from "https://mdwiki.org/w/index.php?title=Sodium_phenylbutyrate/ursodoxicoltaurine&oldid=1405816"